周剂量奈达铂增敏放疗食管癌的临床观察  

Clinical observation of weekly Nedaplatin combined with radio therapy for patients with esophageal carcinoma

作　　者：何学军[1] 崔林[1] 张志胜[1] 刘建军[1] 

机构地区：[1]江苏省姜堰市人民医院肿瘤科,江苏姜堰225500

出　　处：《中国医药导报》2012年第14期71-72,共2页China Medical Herald

摘　　要：目的探讨单纯放疗与周剂量奈达铂增敏放疗食管癌的疗效和毒副反应。方法收集我院2007年1月~2009年12月的肿瘤科住院食管癌患者128例,随机分成对照组和观察组。对照组给予单纯放射治疗方案;观察组在给予放射治疗的同时,第1天开始给予注射用奈达铂40 mg静脉滴注,每周用药1次,共6次。治疗结束评价近期疗效,同时统计分析治疗过程中发生的不良反应。结果对照组近期治疗有效率为81.25%,而观察组则达96.88%（P〈0.05）;观察组患者的不良反应主要以骨髓抑制以及食管炎较为多见,虽明显高于对照组,但是经相应处理均可恢复。结论周剂量奈达铂增敏放疗食管癌疗效显著,值得临床推广使用。Objective To study the efficacy and the toxic reaction of radiotherapy and Nedaplatin combined with radiotherapy for esophageal carcinoma.Methods From January 2007 to December 2009,128 patients with esophageal carcinoma hospitalized in our department of oncology were randomly divided into two groups.The control group was treat with radiotherapy,the experimental group was received Nnedaplatin（40 mg） once a week last for 6 weeks besides radiotherapy.The short-term efficacy and the toxic reaction were evaluate when the treatment was completed.Results The short-term response rate of the control group and the experimental group were 81.25% and 96.88% respectively（P 0.05）.The major toxic reaction of experimental group were bone marrow suppression and esophagitis,and almost all of them were improved after symptomatic supportive treatments,although its incidence rate is higher than in control group.Conclusion Weekly nedaplatin combined with radiation therapy has significant curative effect on patients with esophageal carcinoma,and it worth further widely using.

关 键 词：奈达铂 增敏放疗 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]